15 results about "Innate immune system" patented technology

The application discloses an immunoregulatory antibacterial peptide targeting LPS and a preparation method and application thereof, and belongs to the technical field of biology. The amino acid sequence of the antibacterial peptide FF2 is shown as SEQ ID No. 1, and the antibacterial peptide FF2 of the application can specifically target the bacterial membrane surface component LPS to make the bacterial membrane leak and inhibit the growth of bacteria. The antibacterial peptide can capture bacteria and trigger the innate immune system to achieve the antibacterial purpose, and can also target the bacterial membrane to break the membrane and kill bacteria, thereby fully avoiding the killing of beneficial bacteria in the host body, avoiding the overuse of the antibacterial peptide, effectively reducing the generation of drug resistance, and mobilizing the immune function of the body to synergistically resist bacterial infection. In conclusion, the antibacterial peptide FF2 is a targeted LPS forming nanofiber antibacterial peptide with immunoregulatory function, which has great development potential and high application value.

In one aspect, the invention provides a composition comprising at least one monocyte comprising an agent that increases monocyte homing to a site of injury, and an effective amount of a drug. In another aspect, the invention provides a method of using the composition to deliver a drug to a site of injury.

The present application belongs to the field of functional substance research, and particularly relates to a kind of nutritional composition for regulating immunity and purposes thereof.The nutritional composition provided by the present application comprises essential active ingredients shown in (I) and (II) as follows: (I) lysophosphatidyl ethanolamine; (II) 2'-FL; and in the nutritional composition, the mass ratio of the essential active ingredients shown in (I) to the essential active ingredients shown in (II) is 1:(1-2000). Lysophosphatidyl ethanolamine and 2'-FL are compounded, which can take T cell development activation as core, promote the overall construction and functional regulation of adaptive immune and innate immune system.

The invention discloses a composition capable of achieving double benefits of treatment and immune memory and application of the composition, and belongs to the technical field of biological medicine, and the pharmaceutical composition is composed of 5-carboxyl-8-hydroxyquinoline or pharmaceutically acceptable salt thereof and an anti-tumor drug nano preparation. Preferably, the doxorubicin liposome is composed of 5-carboxyl-8-hydroxyquinoline or a pharmaceutically acceptable salt thereof and a sialic acid functional group modified doxorubicin liposome. The composition can promote antigen presenting cell functions, enhance T cell activity, strengthen T cell memory formation, induce deep remodeling of an immunosuppression microenvironment and training immunity of a congenital immune system, generate strong immune memory, realize comprehensive killing of homologous or heterologous tumors, and has a good application prospect. The recurrence of primary tumors, the generation of secondary primary cancers and the attack of other newborn cancers are prevented.

The invention discloses an LPS-targeted immunoregulation antibacterial peptide as well as a preparation method and application thereof, and belongs to the technical field of biology. The amino acid sequence of the antibacterial peptide FF2 is shown as SEQ ID No.1. The antibacterial peptide FF2 can specifically target a bacterial membrane surface component LPS, so that the bacterial membrane leaks, and bacterial growth is inhibited. The antibacterial aim can be achieved when bacteria are captured and a congenital immune system is triggered, membrane rupture sterilization can be carried out by targeting a bacterial membrane, killing of beneficial bacteria in a host body is fully avoided, meanwhile, excessive use of antibacterial peptide is avoided, generation of drug resistance is effectively reduced, and the immune function of the body is mobilized to resist bacterial infection in a synergistic mode. In conclusion, the antibacterial peptide FF2 is a nanofiber antibacterial peptide formed by targeting LPS, which has great development potential and relatively high application value and has an immunoregulation function.

This invention belongs to the field of functional substance research, specifically relating to a nutritional composition that helps enhance immunity and its uses. The nutritional composition provided by this invention comprises the essential active ingredients shown in (I) and (II) below: (I) lysophosphatidylethanolamine; (II) lactoferrin; wherein, the essential active ingredient shown in (I) contains at least unsaturated lysophosphatidylethanolamine, and the fatty acid chain length of the unsaturated lysophosphatidylethanolamine is 14-22 carbon atoms, and in the nutritional composition, the mass ratio of the essential active ingredient shown in (I) to the essential active ingredient shown in (II) is 1:(0.1-1500). The combination of unsaturated lysophosphatidylethanolamine with a specific fatty acid chain length and lactoferrin can promote the comprehensive construction and functional regulation of adaptive and innate immune systems, with T cell development and activation as the core.

The present invention provides a kind of bacterial microenvironment responsive immunomodulatory antimicrobial peptide and its preparation method and application, belong to the field of bioengineering, its sequence is shown in SEQ ID No.1, its N-terminus is connected to the carboxyl group of indole 3-propionic acid, and the phenylalanine in the sequence is D-phenylalanine. Also disclosed is the application of the antimicrobial peptide of the present invention in the preparation of a drug for treating infectious diseases caused by Escherichia coli. The antimicrobial peptide of the present invention does not have direct bactericidal activity under physiological conditions, has a good antibacterial effect (16 μM) on Escherichia coli under acidic conditions, and has a macrophage immune response, promotes the phagocytic ability of macrophages to bacterial clusters. Therefore, the antimicrobial peptide of the present invention has selective bactericidal function, can coordinate the innate immune system, can effectively reduce bacterial selective pressure, and solves the problem of drug resistance.

The complement system is part of the innate immune system and is highly regulated by regulatory proteins belonging to the Regulators of Complement Activation (RCA) family. It is known that lack of regulation causes damage to host cells and deficiencies in the regulation is also linked to diseases such as age-related macular degeneration, atypical hemolytic uremic syndrome, and dense deposit disease. The regulatory proteins primarily include decay-accelerating factor (DAF; CD55), membrane cofactor protein (MCP; CD46), complement receptor 1 (CR1; CD35), factor H (FH) and C4b-binding protein (C4BP). Structurally, these proteins are composed of repeating complement control protein (CCP) domains where 2-4 successive domains contribute to the regulatory functions termed as decay-accelerating activity (DAA) and cofactor activity (CFA). However, no four-domain chimeric protein currently exists having both strong DAA (CP-DAA and AP-DAA) and strong CFA (C3b-CFA and C4b-CFA). Therefore, chimeric protein DCP (i.e., a dual-activity regulator) was created.

Complement is an arm of the innate immune system that plays an important role in defending the body against infectious agents. Although compositions that inhibit complement are known, there remains a need for compositions that can acutely inhibit complement. Methods and compositions comprising PEGylated compstatin analog for inhibiting complement are described.

To provide a method for treating a host with a cancer or tumor that increases the preservation of the host's innate immune system during and / or after chemotherapy.SOLUTION: The addition of a selective, fast-acting, short half-life CDK 4 / 6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4 / 6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.SELECTED DRAWING: Figure 1

The invention discloses a polypeptide and application thereof. The amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1. The polypeptide provided by the invention can activate an MAPK signal channel and active oxygen accumulation of wheat, namely, the innate immune system of the wheat can be obviously activated, so that the resistance of the wheat to fusarium graminearum and pseudofusarium graminearum is improved. An immunity inducer developed by using the polypeptide has a good application prospect in prevention and treatment of wheat scab and basal stem rot.

Therapeutic modalities are provided for targeting adoptive cellular therapies to specific sites of disease, involving the use of specific repertoirs of PRR ligands. In effect, innate immune system signaling is provoked so as to facilitate the homing of adoptive immune cells to sites of disease, for example to the site of a solid tumor.

An extended release immunomodulatory implant operatively arranged to facilitate bone morphogenesis, including an inner portion including one or more interleukins, and an outer portion surrounding the inner portion, the outer portion including an antigen operatively arranged to activate an innate immune system.

The present invention relates to a novel compound of formula (I) and its composition: [Formula 1] TIFF2026513467000023.tif57115[in the formula, X is a halogen, alkyl, alkyloxy, alkylcarbonyl, alkyloxycarbonyl, alkenyl, alkenyloxy, or alkenylcarbonyl; Y is a hydroxyl or alkoxy group; R is phenyl, cyanophenyl, or halogenated phenyl; R 1 [These are alkyl, branched alkyl, alkenyl, alkynyl, cycloalkyl, alkyloxy, alkylcarbonyl, alkyloxycarbonyl, alkenyloxy, alkenylcarbonyl, phenyl, phenylalkyl, dialkylphenyl, benzyl, or benzylalkyl]. The present invention also relates to the use of compounds of formula (I) and compositions thereof as immunomodulators useful for restoring the adaptive and innate immune systems to healthy baseline ranges. The present invention also relates to the use of compounds of formula (I) and compositions thereof in the treatment of undesirable immune-mediated physiological conditions such as inflammation, viral infections, and cancer, and in other medical applications.